65340-70-7

Basic information

• Product Name: 6-BROMO-4-CHLOROQUINOLINE
• Synonyms: BUTTPARK 23\09-04;4-CHLORO-6-BROMOQUINOLINE;6-BROMO-4-CHLOROQUINOLINE;6-Bromo-4-chloroquinoline ,97%;6-Bromo-4-chloroquinoline ,98%;6-Bromo-4-chloro-1-azanaphthalene;4--6-broMinechlorinequinoline;Quinoline,6-bromo-4-chloro-
• CAS NO: 65340-70-7
• Molecular Formula: C₉H₅BrClN
• Molecular Weight: 242.5
• EINECS: -0
• Mol File: 65340-70-7.mol
• Article Data: 20

Chemical Properties

• Melting Point: 110-112℃
• Boiling Point: 314.584 °C at 760 mmHg
• Flash Point: 144.056 °C
• Appearance: /
• Density: 1.673 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Toluene
• PKA: 2.76±0.16(Predicted)
• CAS DataBase Reference: 6-BROMO-4-CHLOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-CHLOROQUINOLINE(65340-70-7)
• EPA Substance Registry System: 6-BROMO-4-CHLOROQUINOLINE(65340-70-7)

Safety Data

• Hazard Codes: T
• Statements: 25-20/22
• Safety Statements: 45-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 65340-70-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H5BrClN/c10-6-1-2-9-7(5-6)8(11)3-4-12-9/h1-5H

Upstream product

• 145369-94-4 6-bromoquinolin-4-ol 
• 98948-95-9 6-bromo-4-hydroxyquinoline-3-carboxylic acid 
• 106-40-1 4-bromo-aniline 
• 1320361-74-7 ethyl 3-(4-bromoanilino)propenoate 
• 98948-95-9 6-bromo-1,4-dihydro-4-oxo-3-quinoline carboxylic acid 
• 79607-23-1 ethyl 6-bromo-4-oxo-1,4-dihydro-quinoline-3-carboxylate 
• 19056-84-9 diethyl 2-[(p-tolylamino)methylidene]malonate 
• 187278-01-9 5-(((4-bromophenyl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 145369-94-4 6-bromo-3-quinolinecarboxylic acid-4-ol 
• 101937-44-4 diethyl 2-((4-bromophenylamino)methylene)malonate 
• 122794-99-4 6-bromo-4-hydroxyquinoline-3-carboxylic acid ethyl ester 
• 29124-64-9 N-(2-acetyl-4-bromophenyl)acetamide 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 878276-92-7 4-chloro-6-(4-chlorophenyl)quinoline 
• 500127-41-3 4-chloro-6-(4-methoxyphenyl)quinoline 
• 474707-20-5 6-bromo-4-(morpholin-4-yl)quinoline 
• 879324-21-7 6-bromo-4-phenoxyquinoline 
• 144653-40-7 C₂₀H₂₁BrN₄ 
• 749916-89-0 4-chloro-6-(4-tolyl)quinoline 
• 5443-23-2 4-chloro-6-phenylquinoline 
• 676256-25-0 4-chloroquinoline-6-carbaldehyde 
• 879323-85-0 6-bromo-4-cyclohexylmethoxy-quinoline 
• 927801-23-8 6-bromo-4-iodoquinoline 
• 1551455-21-0 N-(2-methoxy-5-(4-((trimethylsilyl)ethynyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1551455-28-7 2-fluoro-N-(2-methoxy-5-(4-((trimethylsilyl)ethynyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1551453-19-0 2,4-difluoro-N-(5-(4-(3-hydroxyprop-1-yn-1-yl)quinolin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1551454-59-1 2,4-difluoro-N-(2-methoxy-5-(4-((trimethylsilyl)ethynyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 

Relevant articles and documents

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

PI3 kinase modulators and methods of use thereof, and use thereof

The invention belongs to the field of medicines, concretely relates to a compound for treating cancer, a composition and an application of the composition and particularly relates to a PI3 kinase regulator as well as a use method and application of the PI3 kinase regulator. The invention provides a compound as shown in the formula (I), a pharmaceutically accepted salt of the compound and a pharmaceutical preparation of the compound, wherein the compound is used for regulating the activity of protein kinase and intercellular or intracellular signal response. The invention also relates to a pharmaceutical composition containing the compound and a method for treating high-proliferative diseases of mammals and particularly human beings by using the pharmaceutical composition as shown in the formula (I).

Indolo[3,2-c]quinoline G-quadruplex stabilizers: A structural analysis of binding to the human telomeric G-quadruplex

A library of 5-methylindolo[3,2-c]quinolones (IQc) with various substitution patterns of alkyldiamine side chains were evaluated for G-quadruplex (G4) binding mode and efficiency. Fluorescence resonance energy transfer melting assays showed that IQcs with a positive charge in the heteroaromatic nucleus and two weakly basic side chains are potent and selective human telomeric (HT) and gene promoter G4 stabilizers. Spectroscopic studies with HT G4 as a model showed that an IQc stabilizing complex involves the binding of two IQc molecules (2,9-bis{[3-(diethylamino)propyl]amino}-5-methyl-11H-indolo[3,2-c]quinolin-5-ium chloride, 3 d) per G4 unit, in two non-independent but equivalent binding sites. Molecular dynamics studies suggest that end-stacking of 3 d induces a conformational rearrangement in the G4 structure, driving the binding of a second 3 d ligand to a G4 groove. Modeling studies also suggest that 3 d, with two three-carbon side chains, has the appropriate geometry to participate in direct or water-mediated hydrogen bonding to the phosphate backbone and/or G4 loops, assisted by the terminal nitrogen atoms of the side chains. Additionally, antiproliferative studies showed that IQc compounds 2 d (2-{[3-(diethylamino)propyl]amino}-5-methyl-11H-indolo[3,2-c]quinolin-5-ium chloride) and 3 d are 7- to 12-fold more selective for human malignant cell lines than for nonmalignant fibroblasts.